A Systematic Review and Meta-analysis of Prognostic Biomarkers in Resectable Esophageal Adenocarcinomas

Overview

Journal Sci Rep

Specialty Science

Date 2018 Sep 7

PMID 30185893

Citations 18

Authors

Aafke Creemers

Eva A Ebbing

Thomas C Pelgrim

Sjoerd M Lagarde

Faridi S van Etten-Jamaludin

Mark I van Berge Henegouwen

Maarten C C M Hulshof

Kausilia K Krishnadath

Sybren L Meijer

Maarten F Bijlsma

Martijn G H van Oijen

Hanneke W M van Laarhoven

Affiliations

Soon will be listed here.

Abstract

Targeted therapy is lagging behind in esophageal adenocarcinoma (EAC). To guide the development of new treatment strategies, we provide an overview of the prognostic biomarkers in resectable EAC treated with curative intent. The Medline, Cochrane and EMBASE databases were systematically searched, focusing on overall survival (OS). The quality of the studies was assessed using a scoring system ranging from 0-7 points based on modified REMARK criteria. To evaluate all identified prognostic biomarkers, the hallmarks of cancer were adapted to fit all biomarkers based on their biological function in EAC, resulting in the features angiogenesis, cell adhesion and extra-cellular matrix remodeling, cell cycle, immune, invasion and metastasis, proliferation, and self-renewal. Pooled hazard ratios (HR) and 95% confidence intervals (CI) were derived by random effects meta-analyses performed on each hallmarks of cancer feature. Of the 3298 unique articles identified, 84 were included, with a mean quality of 5.9 points (range 3.5-7). The hallmarks of cancer feature 'immune' was most significantly associated with worse OS (HR 1.88, (95%CI 1.20-2.93)). Of the 82 unique prognostic biomarkers identified, meta-analyses showed prominent biomarkers, including COX-2, PAK-1, p14ARF, PD-L1, MET, LC3B, IGFBP7 and LGR5, associated to each hallmark of cancer.

Citing Articles

The landscape of circulating tumor HPV DNA and TTMV-HPVDNA for surveillance of HPV-oropharyngeal carcinoma: systematic review and meta-analysis.

Campo F, Iocca O, Paolini F, Manciocco V, Moretto S, De Virgilio A J Exp Clin Cancer Res. 2024; 43(1):215.

PMID: 39095868 PMC: 11297591. DOI: 10.1186/s13046-024-03137-1.

Crosstalk between Cancer Cells and Cancer-Associated Fibroblasts Mediated by TGF-β1-IGFBP7 Signaling Promotes the Progression of Infiltrative Gastric Cancer.

Hong Z, Xie W, Zhuo H, Wei X, Wang K, Cheng J Cancers (Basel). 2023; 15(15).

PMID: 37568781 PMC: 10417438. DOI: 10.3390/cancers15153965.

Tumor Markers and Their Prognostic Value in Sinonasal ITAC/Non-ITAC.

Veuger J, Kuipers N, Willems S, Halmos G Cancers (Basel). 2023; 15(12).

PMID: 37370810 PMC: 10296805. DOI: 10.3390/cancers15123201.

IGFBP7 remodels the tumor microenvironment of esophageal squamous cell carcinoma by activating the TGFβ1/SMAD signaling pathway.

Li X, Zhang J, Wu Y, Ma C, Wei D, Pan L Oncol Lett. 2022; 24(2):251.

PMID: 35761941 PMC: 9214703. DOI: 10.3892/ol.2022.13371.

Expression of Neighbor of Punc E11 (NOPE) in early stage esophageal adenocarcinoma is associated with reduced survival.

Kutting F, Gebauer F, Zweerink S, Kramer L, Schramm C, Quaas A Sci Rep. 2022; 12(1):3584.

PMID: 35246597 PMC: 8897453. DOI: 10.1038/s41598-022-07580-y.

References

Dong H, Guo H, Xie L, Wang G, Zhong X, Khoury T . The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. PLoS One. 2013; 8(5):e62986. PMC: 3643958. DOI: 10.1371/journal.pone.0062986. View

Rauser S, Weis R, Braselmann H, Feith M, Stein H, Langer R . Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res. 2007; 13(17):5115-23. DOI: 10.1158/1078-0432.CCR-07-0465. View

Langer R, Rauser S, Feith M, Nahrig J, Feuchtinger A, Friess H . Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol. 2011; 24(7):908-16. DOI: 10.1038/modpathol.2011.52. View

Rustgi A, El-Serag H . Esophageal carcinoma. N Engl J Med. 2014; 371(26):2499-509. DOI: 10.1056/NEJMra1314530. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Bartley A, Washington M, Colasacco C, Ventura C, Ismaila N, Benson 3rd A . HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017; 35(4):446-464. DOI: 10.1200/JCO.2016.69.4836. View

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

Prins M, Ruurda J, van Diest P, van Hillegersberg R, Ten Kate F . The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol. 2013; 24(5):1290-7. DOI: 10.1093/annonc/mds640. View

Hu Y, Correa A, Hoque A, Guan B, Ye F, Huang J . Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2010; 128(1):132-43. PMC: 2937084. DOI: 10.1002/ijc.25330. View

10.

Bhandari P, Bateman A, Mehta R, Stacey B, Johnson P, Cree I . Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer. 2006; 6:134. PMC: 1481577. DOI: 10.1186/1471-2407-6-134. View

11.

Langer R, Feith M, Siewert J, Wester H, Hoefler H . Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008; 8:70. PMC: 2270853. DOI: 10.1186/1471-2407-8-70. View

12.

Phillips B, Tubbs R, Rice T, Rybicki L, Plesec T, Rodriguez C . Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2012; 26(3):299-304. DOI: 10.1111/j.1442-2050.2012.01369.x. View

13.

Huang Y, Peters C, Fitzgerald R, Gjerset R . Progressive silencing of p14ARF in oesophageal adenocarcinoma. J Cell Mol Med. 2008; 13(2):398-409. PMC: 3098888. DOI: 10.1111/j.1582-4934.2008.00336.x. View

14.

Maru D, Luthra R, Correa A, White-Cross J, Anandasabapathy S, Krishnan S . Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009; 115(7):1576-85. DOI: 10.1002/cncr.24122. View

15.

Dong H, Xie L, Tang C, Chen S, Liu Q, Zhang Q . Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma. Clin Transl Oncol. 2013; 16(9):783-91. DOI: 10.1007/s12094-013-1149-3. View

16.

Aichler M, Motschmann M, Jutting U, Luber B, Becker K, Ott K . Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget. 2014; 5(16):6620-32. PMC: 4196151. DOI: 10.18632/oncotarget.2268. View

17.

Lui N, van Zante A, Rosen S, Jablons D, Lemjabbar-Alaoui H . SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study. BMJ Open. 2012; 2(6). PMC: 3532995. DOI: 10.1136/bmjopen-2012-001624. View

18.

von Rahden B, Kircher S, Kafka M, Stuermer L, Reiber C, Gattenlohner S . Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa. Cancer Biomark. 2011; 7(6):285-94. DOI: 10.3233/CBM-2010-0192. View

19.

Borg D, Hedner C, Gaber A, Nodin B, Fristedt R, Jirstrom K . Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomark Res. 2016; 4:10. PMC: 4867989. DOI: 10.1186/s40364-016-0064-5. View

20.

Goh X, Rees J, Paterson A, Chin S, Marioni J, Save V . Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut. 2011; 60(10):1317-26. DOI: 10.1136/gut.2010.234179. View